ALG-000184-201 is a multi-part, double blind, randomized, placebo-controlled Phase 1 study (NCT04536337)

**BASELINE CHARACTERISTICS**

- HBeAg positive subjects were mostly male, all Asian with a BMI ≥ 25 kg/m², HBV genotype B or C, and high mean HBV DNA, RNA and HBeAg levels.

**PHARMACOKINETICS**

- Plasma ALG-001075 exposure increased proportionally to dose/exposure level may be engaging the CAM 2nd MoA.

**RESULTS**

### ANTIMATERIAL ACTIVITY: HBV DNA and HBV RNA

- **HBV DNA**
  - Mean (SEM) decline of 0.79 ± 0.13 log10 IU/mL
  - Among the 12 subjects enrolled in the 300 mg dose cohort, only 7 were evaluable. Two subjects had missing laboratory data due to prolonged COVID lockdown in China, 1 subject was withdrawn from placebo and 1 subject had missing data at baseline.

**CONCLUSIONS**

- Oral daily dosing for 28 days with 100 mg and 300 mg of ALG-000184 in HBeAg positive CHB subjects was generally well tolerated with a favorable PK profile.

**ACKNOWLEDGMENTS**

The authors wish to thank the subjects for participating in this clinical study. The Sponsor is grateful to the staff of the clinical sites and to Novolex, Kingmed and Tigemed for assisting in the conduct of the study. The authors also wish to thank Aligos team members Chris Burnett and Genevieve Harrington for their aid in the conduct of the study.

**REFERENCES**


**CONTACT INFORMATION**

Benedetta Massetto (bmassetto@aligos.com)

**SUPPORTING MATERIALS**

Hua J., AbbVie; Arturko, Bristol Myers Squibb; Gilead Sciences, Johnson & Johnson; Rohoch. Nu J: Assembly Biosciences, Shanghai Zhimin BioPharma.

**DISCLOSURES**

- AbbVie, Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Maner, Merck, Merck Sharp and Dohme, Roche, Roche Diagnostics, Shanghai Zhimin BioPharma.
- AbbVie, Arturko, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Merck & Co Inc, Merck KGaA, Merck Sharp & Dohme, Roche, Roche Diagnostics, Shanghai Zhimin BioPharma, Virginia Bio.
- AbbVie, Arturko, Atalanta, Johnson & Johnson, Merck, Merck & Co Inc, Merck KGaA, Merck Sharp & Dohme, Roche, Roche Diagnostics, Shanghai Zhimin BioPharma.
- AbbVie, Arturko, Atalanta, Johnson & Johnson, Merck, Merck & Co Inc, Merck KGaA, Merck Sharp & Dohme, Roche, Roche Diagnostics, Shanghai Zhimin BioPharma.